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Abstract.  A  hitherto unknown function for trans- 
glutaminase  (TGase; R-glutaminyl-peptide:  amine 
3,-glutamyltransferase,  EC 2.3.2.13) was found in the 
conversion of latent transforming  growth factor-/3 
(LTGF-/3) to active TGF-B by bovine aortic endothelial 
cells (BAECs). The cell-associated, plasmin-mediated 
activation of LTGF-/3 to TGF-13 induced either by 
treatment of BAECs with retinoids or by cocultures of 
BAECs and bovine smooth muscle ceils (BSMCs) was 
blocked by seven different inhibitors of TGase as well 
as a neutralizing  antibody to bovine endothelial cell 
type II TGase.  Control experiments indicated that 
TGase inhibitors and/or a neutralizing  antibody to 
TGase did not interfere with the direct action of TGF- 
~, the release of LTGF-B from cells, or the activation 
of LTGF-B by plasmin or by transient acidification. 
After treatment with retinoids, BAECs expressed in- 
creased levels of TGase coordinate with the generation 
of TGF-B, whereas BSMCs and bovine embryonic skin 
fibroblasts, which did not activate LTGF-/3 after treat- 
ment with retinoids,  did not. Furthermore,  both TGase 
inhibitors and a neutralizing  antibody to TGase poten- 
tiated the effect of retinol in enhancing plasminogen 
activator (PA) levels in cultures of BAECs by sup- 
pressing the TGF-B-mediated enhancement of PA 
inhibitor-I  (PAl-I) expression. These results indicate 
that type II TGase is a component required for cell 
surface, plasmin-mediated  LTGF-B activation process 
and that increased expression of TGase accompanies 
retinoid-induced activation of LTGF-13. 
T 
1sstJ~ type II transglutaminase  (TGase; R-glutaminyl- 
peptide: amine -t-glutamyltransferase,  EC 2.3.2.13) is 
a member of the TGase family that catalyze Ca2÷-de  - 
pendent  acyl  transfer  reactions  between  -t-carboxamide 
groups of the glutamine  residues in peptides and either pri- 
mary amines or e-amino groups of the lysine residues in pep- 
tides, resulting in the formation of new "t-amides of glutamic 
acid  or  e-(-t-glutamyl)lysine  bonds  and  ammonia  (Folk, 
1980; Lorand and Conrad,  1984; Greenberg etal.,  1991). 
The molecular structure of type II TGase has been reported 
(Ikura et al.,  1988; Gentile et al.,  1991; Nakanishi  et al., 
1991). Type II TGase has a wide distribution;  it is found in 
liver (Folk, 1980; Ikura et al., 1988), epidermal cells (Lichti 
etal.,  1985), erythrocytes (Signorini  et al., 1988), macro- 
phages (Chiocca et al., 1989; Gentile etal., 1991), and many 
cancer cells including HL-60 myeloid cells (Chiocca et al., 
1989).  Furthermore,  various organs  express  type II TGase 
(Folk, 1980) due to its occurrence in ubiquitous cell types 
such as endothelial ceils (ECs), smooth muscle cells (SMCs), 
and certain  perivascular fibroblasts  (Kojima  et al,,  1987; 
Greenberg et al.,  1987; Korner etal.,  1989; Thom~y and 
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Fdstis,  1989; Gentile etal.,  1991). Whereas physiological 
roles of  two types of  TGases have definitively been described, 
e.g., the formation  of cross-linkages  between fibrin  mole- 
cules by plasma Factor XIIIa (Lorand and Conrad,  1984; 
Greenberg etal., 1991) and the formation of cross-linked en- 
velopes during  epidermal cell differentiation  by tissue type 
I TGase (Thacher and Rice, 1985), the physiological role of 
type II TGase has not yet been established except for the for- 
mation  of cross-links  in  erythrocyte membrane  proteins 
(Folk, 1980; Lorand and Conrad,  1984). One putative role 
for type II TGase is an involvement in the regulation  of cell 
growth and differentiation (Birckbichler and Patterson,  1978; 
Chiocca etal., 1989; Suedhoffet al., 1990). This hypothesis 
was derived from the observation that when cellular TGase 
levels  are  high,  cell  growth  is  suppressed  and/or  cell 
differentiation  is induced.  In some of the experiments  de- 
signed to test this hypothesis,  cells were treated  with reti- 
noids,  compounds that have profound effects on the regula- 
tion of cell growth and differentiation  (Roberts and Sporn, 
1984), to increase  TGase levels. 
Recently,  retinoids  were  also  shown  to  increase  the 
production of active  TGF-/3 in  osteoclasts (Oreffo  et al., 
1989), keratinocytes  (Glick et al., 1989), and ECs (Kojima 
and Rifldn,  1993). The TGF-/~ family consists of a number 
of related,  but  functionally  distinct,  25-kD  homodimers 
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three subtypes (TGF-/31, -/32, and -/33) have been isolated 
(Roberts  and Sporn,  1990).  TGF-/3 has potent regulatory 
effects on both cell growth and differentiation. It can either 
promote or inhibit cell growth depending upon the cell type 
and culture conditions (Barnard et al.,  1990;  Roberts and 
Sporn, 1990). TGF-/3 also has been reported to increase type 
I/TGase levels  in normal human keratinocytes (George et 
al., 1990). One cell type whose growth is inhibited by TGF-/3 
is ECs. TGF-/3 inhibits EC proliferation, migration, and, in 
bovine aortic ECs (BAECs), the production of plasminogen 
activator (PA),  whereas it stimulates the production of PA 
inhibitor-1 (PAI-1) and cell matrix components such as colla- 
gen and/or fibronectin (Rifldn et al.,  1991). A critical step 
in the regulation of TGF-/3 action is the activation of the la- 
tent molecule. TGF-/3 is synthesized and secreted by most 
normal and neoplastic cell types, including ECs, in a biologi- 
cally latent, high molecular weight form (LTGF-/3) that can 
not bind to TGF-/3 receptors (Barnard et al., 1990; Roberts 
and Sporn,  1990).  LTGF-/3 consists of a noncovalent com- 
plex in which the 25-kD homodimeric active TGF-/3 is non- 
covalenfly associated with a dimer of its precursor propep- 
tide called the  latency associated peptide  (LAP:  75-kD) 
based on its ability to sustain latency (Roberts and Sporn, 
1990). LAP, in turn, is disulfide-bonded to a second, struc- 
turally unrelated protein  of 135'~180-kD  called  LTGF-/3 
binding protein (Kanzaki et al., 1990). The nature of the ac- 
tivation mechanism of LTGF-/3 in vivo is unclear. In vitro, 
LTGF-/3 is  activated by transient acidification (pH  2)  or 
alkalization (pH 12), which probably disrupts the noncova- 
lent interactions between active TGF-B and LAP, releasing 
the TGF-I~ molecule (Barnard  et al.,  1990;  Roberts  and 
Sporn,  1990),  or by proteases, specifically plasmin, which 
may cleave LAP within its aminoterminal region and release 
active TGF-/3 (Lyons et al., 1988, 1990). Recently, our labo- 
ratory and the laboratory of P. DAmore have described the 
activation  of  L'I~F-/3  under  physiological  conditions  in 
cocultures of ECs with either pericytes or SMCs (Sato and 
Rifkin,  1989;  Antonelli-Orlidge et  al,,  1989).  Both  cell 
types were shown to produce LTGF-/3 and activation ap- 
peared to require cell-cell contact. Activation requires plas- 
min formed from serum plasminogen by PA (Sato and Rif- 
kin,  1989;  Sato et al.,  1990;  Kojima et al.,  1991). The 
activation reaction occurs on the cell surface or matrix. The 
LTGF-~3 is localized at the cell surface by binding to the man- 
nose 6-phosphate (M6P)/insulin-like growth factor-I/recep- 
tor  through  M6P-containing  carbohydrates  in  the  LAP 
(Dennis and Rifkin, 1991), and through interaction with the 
LTGF-/3-binding  protein (Flaumenhafi et al.,  1993). 
Retinoid-induced LTGF-/3 activation in ECs is dependent 
upon plasmin as in the case of cocultures (Sato and Rifkin, 
1989),  and, indeed, retinoids increase surface PA/plasmin 
levels.  However,  the mechanism for LTGF-/3 activation by 
retinoids can not be ascribed solely to enhanced levels of 
PA/plasmin since a direct relationship between PA produc- 
tion and LTGF-/3 activation has not been observed. This im- 
plies the potential existence of an additional component(s) 
required for LTGF-13  activation and whose level in ECs is up- 
regulated by retinoids. Since another property of retinoids is 
their ability to increase expression of cellular type II TGase 
(Lichti et al.,  1985;  Kojima et al.,  1987; Chiocca et al., 
1989;  Nara et al.,  1989;  Suedhoff et al.,  1990),  we have 
tested whether TGase is involved in the activation of LTGF-/3 
in ECs. Here, we demonstrate that type II TGase is required 
for LTGF-/3 activation induced by retinoids as well as by 
cocultures of ECs with SMCs. The requirement for TGase 
in TGF-/3 formation is a hitherto unknown role of this en- 
zyme and may explain the relationship between retinoids, 
TGase, and cell growth. 
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Materials and Methods 
Materials 
All-trans-retinoi, retinoic acid, bacitracin, cystamine, monodansylcadaver- 
ine, and BSA were purchased from Sigma Chem. Co.  (St.  Louis, MO). 
Stock solutions of retinoids were prepared every 2 wk in ethanol and stored 
at -20"C under nitrogen gas. Stock solutions were serially diluted into cul- 
ture medium to yield a final ethanol concentration of 0.5 %. This concentra- 
tion of ethanol did not affect the production or activation of LTGF-/~ (data 
not  shown).  2-[3-(diaUylamino)propionyllbenzothiophene  (DAPBT)  and 
dimethylated  dansylcadaverine  (DMDC)  were  generous gifts  from  Dr. 
Laszlo  Lorand (Northwestern  University,  Evanston, IL).  The inhibitors, 
2 [(2-oxopropyl)thio]imidazolium  derivatives:  1,3,4,5-tetramethyl-2 [(2-oxo- 
propyl)thio]imidazolium  chloride (L68277),  1,3-dimethyl-4,5-diphenyl-2 
[(2-oxopropyl)thio]imidazolium  tdfluoromethylsulfonate (L683685),  and 
1,3-dimethyl-4-phanyl-2[(2-oxopropyl)thiolimidazolium  chloride  (L683- 
696) were kindly supplied  from Dr.  Andrew M.  Stern (Merck Sharp & 
Dohme  Research  Laboratories,  West  Point,  PA).  Recombinant human 
TGF-fll  (rTGF-/~I) was a generous giit from Genentech, Inc.  (South San 
Francisco, CA). Antibody against porcine TGF-~ (t~TGF-/~  IgG), which has 
previously been shown to neutralize porcine, human, and bovine TGF-/~I 
and -62 (Sato and Rifkin, 1989; Roberts et al.,  1990), was obtained from 
R&D Sys.,  Inc.  (Minneapolis, MN). The preparation of antibody against 
bovine EC type II TCrase (otTCactse  IgG) was previously described (Nara et 
al.,  1989). Briefly, cytosol was prepared from retinol-treated bovine ECs 
(10/~M retinol, 2 d) and cytosolic proteins were separated by preparative 
SDS-PAGE. The 80-kD band of TGase, located by Coomassie brilliant blue 
staining of the gel, was excised from the gel and the gel slice containing 
TGase was homogenized with Freund's complete adjuvant and injected sub- 
cutaneously into a rabbit. Immunizations and bleedings were continued bi- 
weekly. IgG fraction was isolated from the serum using protein A-Sepha- 
rose (Pharmacia LKB Biotechnology Inc., Piscataway, NJ). The antibodies 
were shown to be immunospecific  by Western blot of BAEC cytosol and 
microsequencing  of the protein that was isolated by monitoring the immu- 
noreactivity with this antibody. 
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BAECs were isolated and grown in a  modified MEM (aMEM) (GIBCO 
BRL, Gaithersburg, MD) containing 10% calf serum (CS) (ICN Biomedi- 
cals Inc., Costa Mesa, CA). Bovine aortic smooth muscle cells (BSMCs) 
and embryonic skin fibroblasts (BESFs) were isolated and grown in DME 
(Flow Labs. Inc., McLean, VA) containing 10%  CS. 
Preparation of Conditioned  Medium 
Conditioned medium (CM) was prepared as described (Kojima et al., 1991; 
Kojima and Rifkin, 1993).  For retinoid experiments, BAECs were grown 
to confluence in 35-ram dishes, the cultures were rinsed with PBS, pH 7.4, 
and incubated in I ml of serum-free ~MEM containing 0.1% BSA (cxMEM- 
BSA),  and  retinoid or vehicle (0.5%  ethanol) for 24 h.  Thereafter, the 
medium was aspirated, the cultures were washed with PBS, and the cells 
incubated in 1 ml of ~MEM-BSA without retinoid for an additional 12 h 
to  produce CM.  For coculture experiments, BAECs and BSMCs were 
seeded  separately  in  35-mm  dishes (8  cm  2)  at  a  density of 5  ×  104 
cells/cm  2 in ~MEM containing 10% CS, or 3.2  ×  105 BAECs and 0.8  × 
105 BSMCs were seeded in the same 35-mm dishes in c~MEM containing 
10%  CS. After a 2-h incubation to permit the ceils to attach, the cultures 
were rinsed with PBS and incubated in 1 mi of c~MEM-BSA for an addi- 
tionai 6 h to produce CM. The CM was centrifuged to remove cell debris 
and used in assays to detect either TGF-~ or LTGF-/3. For 13H]thymidine 
incorporation assays, CM was prepared in Eagle's modified MEM contain- 
ing 0.1%  BSA. 
Wound Migration Assay  for TGF-~ 
Wound assays for BAEC migration were carried out as described previously 
(Kojima et  al.,  1991).  After a  denuded area was  made in  a  confluent 
monolayer using a razor blade, the cultures were incubated in the presence 
of the additions to be tested for 24 h. The cells were fixed, and the number 
of cells that migrated from the original edge of the wound counted. This 
number is inversely proportional to the amount of TGF-/3 present in CM, 
since TGF-/3 suppresses BAEC migration (Heimark et al., 1986). This assay 
can be used to detect concentrations of TGF-/5 as low as 0.4-0.8 pM (Sato 
et al.,  1990).  The data are presented as the number of cells that have 
migrated >125 tzm from the original edge in order to exclude those ceils 
which moved across the origin before TGF-~ had an effect. The number 
represents the average obtained by counting the ceils in six random fields 
from each of two replicate dishes. 
Cellular PA Assay  for TGF-/3 
This assay was based upon the observation that TGF-/~ suppresses PA levels 
in ECs (Saksela et al., 1987) and can be used to measure the concentration 
of TGF-/~ present  in  CM  (Flaumenhaft  and  Rifkin,  1992).  Confluent 
monolayers of BAECs grown in 96-well culture plates were washed with 
PBS and incubated in 35/zl of CM for 4 h. The ceils were washed with PBS, 
cellular PA extracted into 0.5% Triton X-100 in 0.1 M Tris-HCl, pH 8.1, 
and PA levels of the extracts measured using the 1251-labeled  fibrin plate as- 
say (Gross et al., 1982).  The amount of TGF-/3 in the CM was determined 
by comparison to a standard curve prepared with various concentrations of 
rTGF-~I  in c~MEM-BSA.  The amount of LTGF-/3 in the CM was deter- 
mined in a similar manner after the CM was acidified (pH 2,  1 h at room 
temperature) followed by neutralization. This assay can be used to measure 
TGF-/3 in the 0.08-2.4 pM range. The specificity of the inhibition of PA was 
validated by controls employing ~TGF-/3 IgG added to the CM. Data are 
expressed as the amount of TGF-/3 per  106 cells to compensate for the 
reduction of cell number in retinol-treated cultures (,~15-25%  reduction 
from control cultures; Kojima et al., 1986).  For example, when the concen- 
tration of TGF-~ in 1 ml of CM, collected from confluent cultures of 10  ~ 
cells in a 35-mm dish, is 1 pM (25 pg/ml), this is expressed as 1 fmol/106 
cells. 
pH]Thymidine Incorporation Assay  for TGF-[3 
The inhibition of [3H]thymidine incorporation by CCL-64 mink lung epi- 
tbelial cells as an assay for TGF-~ was carried out according to the method 
of Danielpour et  ai.  (1989).  A  suspension of CCL-64  cells (2  x  105 
cells/ml) was made in DME containing 0.2% FCS and 10 mM Hepes. 40 
ml of this suspension was transferred to each well of a 96-well culture plate. 
After preincubation for 2 h, 35 t~l of CM was added directly to each well 
and the cultures were incubated for 22 h. Thereafter, 15 ~1 of [3H]thymi- 
dine (10 t~Ci/mi) was added directly to each well, and the cultures were in- 
cubated for 4 h at 37°C. Cells were fixed by incubating dishes for 1 h at 
room temperature with 160 t~l of methanol: acetic acid (3:1) directly added 
to the radioactive medium, washed twice with 250 ~1 of 80%  methanol, 
trypsinized, and solubilized into 1% SDS-trypsin solution. Radioactivity in 
the  cell  lysate  was  measured  with  a  Beckman  LS3801  ~-scintillation 
counter. The amount of TGF-/3 in the CM was determined by comparison 
to a standard curve prepared with various concentrations of ffGF-/31 in Ea- 
gle's modified MEM containing 0.1% BSA. This assay can be used to mea- 
sure TGF-/3 in the range of 0.08-2.4 pM. Data are expressed as the amount 
of TGF-/~ per 106 cells as described before. 
Preparation of Cytosol and Membrane 
Extract Fractions 
Cells were scraped from the culture dish with a  rubber policeman and 
washed three times with cold Ca  2+ and Mg2+-free  Hepes buffered saline 
(CMFH buffer:  129  mM NaC1,  5  mM KC1, 0.3  mM Na2HPO4,  1 mM 
NaHCO3, 5 mM glucose, and 25 rnM Hepes, pH 7.4).  The washed cells 
were ruptured in cold CMFH buffer containing 40 #M leupeptin and 2 mM 
PMSF using ultrasonication on ice. The supernatant (cytosol) was obtained 
by centrifugation of the homogenate at 15,000 g for 15 min at 4"C. The pel- 
let was washed with the same buffer, solubilized in CMFH buffer containing 
10 mM CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-l-propanesul- 
fonate), 40/xM leupeptin and 2 mM PMSF, centrifuged at 15,000 g for 15 
min, and the supernatant collected as the soluble membrane extract. 
TGase Assay 
TGase activity was measured as the Ca2+-dependent incorporation of 14C- 
putrescine  (Amersham  Corp.,  Arlington  Heights,  IL)  into  N,N- 
dimethylcasein by a modification of the method described by Nara et al. 
(1989).  The reaction mixture consisted of CMFH buffer containing 5 mM 
CaCI2,  1 mg/ml N,N-dimethylcasein, 20 mM dithiothreitol, 0.8 % (vol/vol) 
glycerol, 250 #M 14C-putrescine  (0.45 #Ci), and the sample, in a final vol- 
ume of 300 #!. The reaction mixtures were incubated for 1 h at 37°C and 
reactions stopped by the addition of 600 t~l of 16.7% TCA with 100 #1 of 
2%  BSA. The precipitate was collected on Whatman GF/C glass filters, 
washed three times with 2 mi of 10% TCA, and the radioactivity measured 
by liquid scintillation counting. TGase activity was expressed as nanomoles 
of putrescine incorporated into casein in 1 h at 37°C per mg of protein of 
sample.  Protein  concentration  was  measured  by  microtiter  plate  BCA 
(Pierce, Rockford, IL) assays using BSA as the standard. 
Reverse l~brin Autography 
Reverse fibrin autography was carried out by the method of Erickson et al. 
(1984).  Briefly,  CM was prepared from BAECs as described in the legend 
for  Fig.  6,  concentrated  10-fold  on  Microcon  concentrator  (Amicon, 
Beverly,  MA), and proteins in CM fractionated through SDS-PAGE with 
10% resolving gels. Gels were washed twice with 2.5% Triton X-100 and 
then with saline, and applied onto fibrin-agar gel containing plasminogen 
and urokinase. The PAI-I was visualized as a lysis-resistant opaque band 
after incubation of the gel at 37°C for 3 h. 
Results 
Effect of Inhibition of TGase Activity on Formation of 
TGF-# by Retinoid-treated ECs 
To test the hypothesis that TGase is involved in the activation 
of LTGF-~ by retinoid-stimulated BAECs, a TGase inhibitor, 
cystamine (Lorand and Conrad,  1984),  was included with 
retinol in the medium of wounded cultures of BAECs and cell 
migration was monitored (Fig. 1). In this system, the genera- 
tion of TGF-~ induced by retinoids can be measured as the 
inhibition  of  cell  migration.  The  addition  of  retinol  to 
wounded cells  in the absence  of cystamine  inhibited cell 
migration by  ,',~40%. The inclusion of c~TGF-/~ IgG abol- 
Kojima et al.  Transglutaminase  in Latent TGF-(3 Activation  441 120-  C~TGFoJ~ IgG 
@ 
' ~  Retlnol  ~o.  CYSt're'he  ...........  ........... 
Cystmm!ne 
20- 
0 
o 
Concentration of Cyst=mh,  e (~ 
Figure 1. Dose-dependent inhibitory effect of cystamine on retinol- 
induced suppression of BAEC migration.  Confluent BAECs were 
wounded as described  in Materials and Methods.  The cells were 
allowed to migrate overnight in the presence of increasing concen- 
trations  of cystamine  with  and  without  2  #M  retinol,  and  the 
monolayers were fixed, stained,  and the number of cells that had 
moved >125/zm from the original wound margin counted. Data are 
expressed as a percent of control using fresh medium containing 
0.5% ethanol. The number of cells that had moved >125 #m in the 
control  was 52.  (o) Increasing  amounts of cystamine alone.  (o) 
Retinol (2 #M) with increasing amounts of cystamine. (=) Retinol 
(2 /zM) with aTGF-/3 IgG (10/.tg/ml). 
ished the inhibitory effect of retinol, indicating that the inhi- 
bition of migration observed in the presence of retinol was 
due to TGF-B. When migration in the presence of retinol plus 
cystamine was monitored, the number of migrating cells in- 
creased  with  increasing  concentrations  of cystamine until 
150 #M and decreased at higher concentrations. The inclu- 
sion of cystamine alone at concentrations <150 #M had little 
effect on cell migration. The inhibitory effect of concentra- 
tions of cystamine >150/~M plus retinol was probably due 
to toxicity. Similar results were obtained in this assay using 
retinol  plus  two  other  TGase  inhibitors,  bacitracin  and 
monodansylcadaverine (Maxfield et al.,  1979;  Lorand and 
Conrad,  1984)  (data not shown). These results suggest that 
the inclusion of TGase inhibitors abolished retinol's capacity 
to stimulate the formation of TGF-B. 
To corroborate this hypothesis, we next included TGase in- 
hibitors during the preparation of CM from retinol-treated 
or untreated BAECs, and measured the effect of the CM on 
BAEC migration in wound assays (Fig. 2). CM from retinol- 
treated cells inhibited test cell migration by 35 % (sample 2). 
This inhibition was due to TGF-B since it was abrogated by 
inclusion  of aTGF-/3 IgG (sample 1/).  Whereas CM pre- 
pared from untreated cells in the presence of each TGase in- 
hibitor had little effect on migration (samples 3, 5,  and 7), 
inclusion of these inhibitors in the medium during the prepa- 
ration of CM from retinol-treated cells suppressed the gener- 
ation of inhibitory activity (samples 4, 6, and 8). In addition, 
the inclusion of c~TGase IgG also alleviated the inhibitory 
effect of retinol on cell migration (sample 10). The effect of 
cystamine was also observed in the inhibition of [3H]thymi- 
dine incorporation by mink lung cells as a measurement of 
TGF-~ (Fig. 3). As seen in the other assays, retinol exposure 
induced TGF-/3 formation (sample 2) and this was blocked 
by the inclusion of cystamine in the initial culture medium 
(sample 4). The effect of retinol was also blocked by ctTGF-B 
IgG (sample 5). Furthermore, the effect of the TGase inhibi- 
tors, DAPBT, L682777,  L683685,  and L683696 was tested 
(Table I). These inhibitors are thought to react specifically 
with the active site of TGase and to suppress TGase activity 
(Lorand et al.,  1987;  Barsigian et al.,  1991).  CM was pre- 
pared from retinol-related BAECs in the presence of the four 
TGase  inhibitors  as  well  as  monodansylcadaverine  and 
dimethylated dansylcadaverine (DMDC), and the amount of 
active TGF-B present in CM was determined by the PA assay. 
DMDC was used as a noninhibitory control for monodansyl- 
cadaverine. Whereas DMDC did not affect retinol-induced 
formation of TGF-B, all of the TGase inhibitors tested sup- 
pressed TGF-B formation to the levels obtained in untreated 
cell CM. The effect of the TGase inhibitors and ctTGase IgG 
was also observed with cells treated with retinoic acid (data 
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Figure 2.  Effects of TGase  inhibitors  and  anti- 
TGase antibody on retinol-induced  formation of 
TGF-/5. Confluent  BAECs  were  incubated  with 
0.5% ethanol (vehicle; samples 1, 3, 5,  7, and 9) 
or with 2/~M retinol (samples 2, 4, 6, 8, and 10) 
for 24 h and CM was prepared in the presence of 
100/~M  TGase inhibitors,  cystamine (samples 3 
and  4),  bacitracin  (samples  5  and  6),  and 
monodansylcadaverine (samples  7 and 8) or 100 
#g/ml of neutralizing antibodies to TGase (sam- 
ples  9  and  10)  as  described  in  Materials  and 
Methods. The CM was tested for TGF-~ activity 
in  wound migration  assays  using  BAECs. Cell 
migration  was expressed as a percent  of control 
using  CM from untreated  cells.  The number of 
cells that had moved >125 #m in the control was 
80.  The formation  of TGF-fl in CM  of retinol- 
treated cells was verified by addition of otTGF-/3 
IgG (10 #g/ml; sample 11) or nonimmune  (N1) 
IgG (10/~g/ml; sample 12) to the CM from retinol- 
treated cells. 
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Figure 3.  Cystamine  inhibition of TGF-/~ forma- 
tion in retinol-treated  BAECs measured by mink 
lung  cell  [3H]thymidine  incorporation  assays. 
Confluent BAECs were treated with 2/zM retinol 
as before and CM was prepared  in the presence 
and the absence of 100 t~M cystamine. The CM 
was tested  for TGF-/~ activity  in mink lung cell 
[3H]thymidine incorporation  assays as described 
in Materials  and Methods.  Sample  1,  CM  from 
control cells; sample 2, CM from retinol-treated 
cells;  sample 3,  CM  from control cells prepared 
in the presence of cystamine; sample 4, CM from 
retinol-treated  cells  prepared  in the  presence  of 
cystamine; and sample 5, CM from retinol-treated 
cells with c~TGF-~ IgG (10/xg/ml). The concentra- 
tions of TGF-/~ in each CM determined by this as- 
say are also  listed.  *0.92  fmol (23.1  pg)/106cells 
is equivalent to  14.3 pg/ml (0.57 pM) of CM/0.62 
x  106  cells/35-mm dish. 
Table I. Effect of TGase Inhibitors on Formation of 
TGF-fl in Retinol-treated BAECs 
Cell culture  TGF-~ 
fmol/l Oscells 
Experiment  1 
Control  0.08  +  0.01 
Retinol  +  DMSO  1.10  +  0.12" 
Retinol  +  DAPBT  <0.08 
Retinol  +  MDC  <0.08 
Retinol  +  DMDC  0.77  +  0.11 
Experiment 2 
Control  <0.08 
Retinol  +  DMSO  0.90  +  0.09 
Retinol  +  L682777  0.21  +  0.03 
Retinol  +  L683685  <0.08 
Retinol  +  L683696  <0.08 
Confluent BAECs were treated with 2 #M retinol for 24 h as before.  CM was 
prepared in the presence of either 0.5% dimethylsulfoxide (DMSO), DAPBT 
(100/~M), monodansylcadaverine (MDC;  100/~M), or DMDC (100/zM)  in 
Experiment  1,  or 0.5%  DMSO,  L682777  (50 /tM),  L683685  (50 #M),  or 
L683696 (50 ttM) in Experiment 2 and the amount of active TGF-13 was deter- 
mined by PA activity assay as described in Materials and Methods. Data are 
expressed as the amount per IO  s cells. 
* 1.10  fmol  (27.5  pg)/lOs cells is equivalent to  22.3  pg/ml (0.89  pM)  of 
CM/0.81  x  lOs cells/35-mm dish. 
not shown). Inhibitors and antibody did not affect the inhibi- 
tion of cell migration or the suppression of PA levels by ei- 
ther  rTGF-/3  or CM  (data not shown).  These results  sug- 
gested that TGase is involved in the formation of TGF-~ in 
retinoid-treated BAECs. 
Specificity of Retinoid Effects 
Because retinoids are known to increase TGase levels in cer- 
tain cells (Kojima et al.,  1987;  Chiocca et al.,  1989;  Nara 
et al.,  1989; Suedhoff et al.,  1990), we measured the levels 
of  TGase  in  both  membrane  and  cytosolic  fractions  of 
BAECs (Table II). Treatment with retinol caused a 2.5-fold 
increase in cytosolic TGase and a 4.3-fold increase in mem- 
brane activity. Exposure of BAECs to retinol also caused a 
twofold increase in PA levels but only a 20% increase in total 
(active and latent) TGF-/~. The effect of retinol showed some 
cell specificity since the stimulation of TGase in BSMCs and 
BESFs was much lower than that observed in BAECs as were 
the levels of PA. The effects of retinol on LTGF-~ activation 
by these three cell types were similar to its effects on TGase 
and PA expression. Retinol induced the formation of active 
TGF-/3  only  in  BAECs.  Only  retinol-treated  BAECs  ex- 
pressed significantly increased levels of PA, TGase, and ac- 
Table IL Comparison between the Effects of  Retinol on TGase and PA Levels and Secretion and Activation  of  LTGF-f3 in 
BAECs, BSMCs, and BESFs 
TGase activity  PA activity  Amount of TGF-B 
Cell  Retinol  Cytosol  Membrane extracts  Medium  Cell lysate  Active  Total 
nmole putrescine/h/mg  protein  U/IO  6 cells  U/mg protein  fmol/lO 6 cells 
BAEC  -  335  +  48  53  +  9  3.3  +  0.7  1.7  +  0.3  <0.08  15.2  +  2.7 
+  825  +  40  229  +  19  6.8  +  0.8  4.0  +  0.6  0.75  +  0.09  19.0  +  1.2 
BSMC  -  13.2  +  1.3  4.8  -1- 0.0  0.02  +  0.00  0.73  +  0.07  0.10  +  0.03  25.0  +  1.2 
+  26.5  +  0.2  6.8  +  2.0  0.06  +  0.01  0.49  +  0.04  <0.08  19.3  +  2.6 
BESF  -  0.07  +  0.01  0.24  "4" 0.02  0  0.05  +  0.01  0.12  +  0.02  12.7  +  3.4 
+  0.07  +  0.01  0.48  +  0.15  0  0.13  +  0.03  0.11  +  0.01  14.8  -k  1.8 
Confluent BAECs, BSMCs, and BESFs were treated with 2 ~M retinol for 24 h as before. CM, cell lysate, cytosol, and membrane extracts were prepared from 
each cell, and amounts of active and total (active and latent)  TGF-B present in CM. PA activity levels in both CM and cell lysate, and TGase activity levels in 
both cytosol and membrane extracts were measured as described in Materials and Methods. Data are expressed as either the amount and activity per los ceils 
or activity per mg protein of sample. 
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Figure 4. Inhibition of TGF-B formation in cocultures of BAECs 
and BSMCs by cystamine and anti-TGase antibody. (A) Dose de- 
pendency of cystamine inhibition: CM was prepared from homo- 
typic and heterotypic cultures of BAECs and BSMCs in the pres- 
ence of increasing  concentrations  of cystamine  as described  in 
Materials  and Methods.  The CM was added to wounded BAEC 
monolayers, and cell migration was quantitated as before. The num- 
ber of cells that had moved >125/~m  was expressed as a percent 
of control using 4:1 mixture of BAEC CM and BSMC CM. The 
number of cells that had moved >125 #m in the control was 50. (o) 
Mixture of BAEC and BSMC CM (4:1) prepared in the presence 
of increasing mounts of cystamine. (o) Coculture CM prepared in 
the presence  of increasing amounts of cystamine.  (n)  Coculture 
CM prepared in the absence of cystamine to which ~TGF-fl IgG 
(10 #g/ml) has been added. (B) Control experiment: Wound assays 
of BAEC migration were performed as before testing the following 
additions: sample 1, control CM that was a 4:1 mixture of BAEC 
CM and BSMC CM; sample 2, cystamine (100 #M) added to con- 
trol CM; sample 3, fl'GF-3 (2 pM) added to fresh medium; sample 
4, cystamine (100 #M) plus frGF-3 (2 pM) added to fresh medium; 
sample 5, coculture CM; sample 6, cystamine (100/~M) added to 
coculture CM; sample 7, coculture CM prepared in the presence 
of  cystamine (100 tzM); sample 8, coculture CM supplemented with 
aTGF-fl IgG (10 #g/ml);  sample 9, coculture CM prepared in the 
presence of offGase  IgG (100/~g/ml); and sample I0, coculture CM 
prepared  in the presence of NI IgG (100 ~g/ml).  The number of 
cells that had moved in the control was 62. 
tive  TGF-3  concomitantly,  although  the  total  amount  of 
TGF-3 produced  was  similar  among  the  three  cell  types 
regardless of the treatment. 
Involvement of TGase in Formation of TGF-3 
by Cocultures 
We previously documented that cocultures of BAECs and 
BSMCs activate LTGF-3 (Sato and Rifldn,  1989).  There- 
fore, we next tested whether cystamine blocked TGF-B for- 
marion in cocultures.  A  result similar to that illustrated in 
Fig.  1 was obtained (Fig. 4 A). Increasing concentrations of 
cystamine added to the medium during the preparation of 
coculture CM abrogated the ability of the CM to suppress 
test cell migration. Control experiments (Fig. 4 B) indicated 
that cystamine did not block the effect of flGF-B (sample 4) 
or CM (sample 6) when it was added directly to wounded 
cells. Cystamine was effective only when included during the 
preparation of CM (sample 7). Similar results were obtained 
using otTGase IgG instead of cystamine during coculture ac- 
tivation of LTGF-3 (Fig. 4 B, sample 9). These results indi- 
cate that cystamine and aTGase IgG block the formation of 
TGF-3 in  the  coculture  system as  well  as  in  the  retinoid 
system. 
Effects of TGase Inhibitor and Antibody on 
LTGF-3 Production 
To  quantify  the  effect  of  TGase  inhibitors  (cystamine, 
DAPBT, and L683685) and c~TGase IgG on the production 
Table IlL Effect of TGase Inhibitor, and oeTGase IgG on 
Production of  Active and Latent TGF-fl  in CM of  BAECs 
Either Treated with Retinol (Experiment 1) or Cocultured 
with BSMCs (Experiment  2) 
Cell culture  Active TGF-3  Total TGF-3 
fraol/lO 6 cells 
Experiment 1 
Control  <0.08  24.7  +  3.2 
Retinol  0.56  +  0.15  31.0  +  1.3 
Retinol  +  Cystamine  0.09  +  0.02  26.0  +  2.5 
Retinol  +  DAPBT  <0.08  19.5  +  3.4 
Retinol  +  DMDC  0.48  +  0.07  19.4  +  2.2 
Retinol  +  I..683685  0.12  ±  0.03  32.6  ±  8.1 
Retinol  +  c~TGase IgG  0. l 1  ±  0.01  24.3  ±  4.3 
Retinol  +  NI IgG  0.78  ±  0.14  26.4  ±  1.1 
Experiment 2 
Control  <0.08  48.0  ±  5.0 
Coculture  0.90  ±  0.04  41.2  +  7.8 
Coculture  +  Cystamine  <  0.08  42.5  +  6.5 
Coculture  +  DAPBT  0.08  ±  0.04  36.1  -i- 3.0 
Coculture  +  DMDC  0.79  +  0.12  33.7  ±  9.1 
Coculture  +  L683685  <0.08  52.9  ±  1.9 
Coculture  +  aTGase IgG  <0.08  43.5  ±  5,5 
Coculture  +  NI IgG  0,87  ±  0.02  44,0  ±  5,0 
(Experiment 1) Confluent BAECs were treated  with 2 #M retinol for 24 h as 
before. CM was prepared in the presence and the absence of either cystamine 
(100/~M), DAPBT (100/~M), DMDC (100/~M), 1,683685 (50/~M), ~TGase 
IgG (100 ~g/ml), or NI IgG (100/~g/ml), and amounts of active and total (ac- 
tive plus latent)  TGF-3 present in CM were determined by PA activity assays 
as described in Materials and Methods. (Experiment 2) CM was prepared from 
cocultares of BAECs and BSMCs in the presence and the absence of the same 
inhibitors or antibody as used in Experiment 1 and amounts of active and total 
TGF-3 were determined. 
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Figure 5. Effect of cystamine and anti-TGase  anti- 
body on PA levels as an inhibitor of endogenous 
formation  of  TGF-/L Confluent  BAECs were 
treated with retinol or vehicle in the presence and 
the  absence  of either  cystamine,  ~TGF-/3 IgG, 
cxTGase IgG, or NI IgG for 2 d in ~MEM-BSA. 
PA activity levels in each medium were assayed as 
described in Materials and Methods and expressed 
as urokinase (UK) units per  10  ~ cells.  Samples 
1-5, vehicle (0.5% ethanol); samples 6-10, retinol 
(2 pM).  Samples 2 and 7, cystamine (100 pM); 
samples 3 and 8, c~TGF-/3  IgG (10 pg/ml); samples 
4 and 9, c~TGase  IgG (100 pg/mi); and samples 5 
and 10, NI IgG (100 #g/ml). 
of LTGF-/3, CM was prepared in the presence of TGase in- 
hibitors or aTGase IgG from either retinol-treated BAECs 
or cocultures of BAECs and BSMCs,  and the amounts of 
both active and total TGF-fl present in CM were measured. 
The results are listed in Table III. In both systems, retinol- 
treated cells or cocultures (Experiments  1 and 2,  respec- 
tively), cystamine, L683685, and o~TGase IgG reduced the 
amount of active TGF-/3 without significantly changing total 
TGF-/3 content, indicating that these compounds blocked the 
formation of TGF-/3 by suppressing LTGF-/3 activation and 
not by suppressing the secretion of LTGF-/3. DAPBT sup- 
pressed the formation of TGF-B but with a reduction in total 
TGF-/3 production of 25-35 %. However, it is unlikely that 
this decrease of LTGF-/3 secretion accounts for 100% inhibi- 
tion of active TGF-B formation, since a  similar degree of 
reduction  in  total  TGF-/3  secretion  was  observed  with 
DMDC which did not completely suppress the activation of 
LTGF-/3. Furthermore, TGase inhibitors  and offGase IgG 
did not interfere with the activation of LTGF-/3 in CM either 
by exogenous plasmin (0.8 U/ml, 2 h at 37°C) or by transient 
acidification  (pH  2,  1  h  at  room temperature)  (data  not 
shown). 
Enhancement of  PA Levels in ECs by Simultaneous 
Addition of Retinol and Inhibitor of LTGF-~ Activation 
Retinoids have been shown to enhance PA synthesis in ECs. 
This effect is often accompanied by increased expression of 
PAI-1 (Kojima et al.,  1986; Kooistra et al.,  1991). We have 
proposed that the coinduction of PAL1 with PA in retinoid- 
treated ECs is the result of TGF-/3 formation induced by reti- 
noids followed by increased PAL1 expression due to TGF-/3 
activity (Kojima and Rifkin, 1993). If this hypothesis is cor- 
rect and if the formation of TGF-/3 requires TGase, the effect 
of retinoids on PA levels should be augmented in the pres- 
ence of TGase inhibitors since PAL1 expression should not 
be increased.  This was tested by an experiment in which 
BAECs were treated with a combination of retinol and either 
cystamine, o~TGF-/3  IgG, offGase IgG, or NI IgG and the PA 
activity levels of CM were measured (Fig. 5). Whereas cys- 
tamine  alone  did  not  increase  PA  levels  (sample  2)  and 
retinol alone increased them by 100% (sample 6), these two 
agents in combination increased PA levels by 260 % (sample 
7).  A  similar result was obtained with the combination of 
retinol and otTGF-/3 IgG (sample 8) or retinol and otTGase 
IgG (sample 9). NI IgG did not enhance the effect of retinol 
(sample 10). Controls of otTGF-/3 IgG, otTGase IgG, and NI 
IgG alone had no effect on basal  PA production (samples 
Figure 6.  Suppression of retinol-induced augmentation of PAI-1 
levels  by  TGase  inhibitors  or  anti-TGase antibody. Confluent 
BAECs were treated with retinol or vehicle in the presence and the 
absence of either c~TGF-/~  IgG, cystamine, L682777, ~TGase IgG, 
or NI IgG for 24 h in aMEM containing 0.1% gelatin. Medium was 
changed and further incubated for another 24 h as before except that 
gelatin was omitted from medium.  This later medium was col- 
lected, concentrated, and subjected to SDS-PAGE. PAI-1 was then 
detected by reverse fibrin autography. Odd number lanes, control 
(C; 0.5% ethanol); Even number lanes, retinol (R; 2 pM).  Lanes 
3 and 4, c~TGF-/3  IgG (50 ttg/ml); lanes 5 and 6, cystamine (100 
/zM); lanes 7 and 8, L682777 (100 pM); lanes 9 and 10, ~'l'Gase 
IgG (100 #g/ml);  and lanes 11 and 12, NI IgG (100 pg/mi). 
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on retinol-induced PA expression is via suppression of in- 
creased PAI-1 levels after retinol-induced TGF-13 formation, 
the amounts of PAI-1 present in CM of cells treated in differ- 
ent ways were measured by reverse fibrin zymography (Fig. 
6). The enhanced production of PAI-I in retinol-treated cul- 
tures can be seen by comparing lanes I and 2. When cultures 
were treated with retinol and either aTGF-13 IgG (lane 4), 
cystamine (lane 6), L682777 (lane 8), or offGase IgG (lane 
10), the normally observed increase in PAI-1 did not occur. 
None of these treatments alone affected basal levels of PAI-1 
production (lanes 3, 5, 7, and 9). Finally, the retinol-induced 
increase in PAI-1 was not blocked by NI IgG (lane 12). These 
results support the hypothesis that TGase is a component re- 
quired for LTGF-13 activation in retinol-treated BAECs. 
Discussion 
The present  study describes  a  novel function for type II 
TGase as a component required for LTGF-~ activation. We 
have demonstrated that TGase inhibitors of two different 
classes,  substrate competitor (monodansylcadaverine) and 
active site-directed inhibitors (cystamine, DAPBT, L682777, 
L683685, and L683696) as well as a neutralizing antibody 
to type II TGase abrogate the activation of LTGF-13 observed 
with both retinoid-treated BAECs and BAEC/BSMC cocul- 
tures.  These  inhibitors  and  the  neutralizing  antibody to 
TGase do not affect the activity of TGF-13, the release of 
LTGF-~, or the activation of LTGF-~ by plasmin or transient 
acidification. The concentrations of TGase inhibitors, cysta- 
mine, bacitracin, and monodansylcadaverine and antibody 
to TGase required for complete inhibition of LTGF-13 activa- 
tion, are consistent with those required for direct inhibition 
of TGases derived from BAECs (data not shown), guinea pig 
liver (Lorand and Conrad, 1984), and CHO cells (Maxfield 
et  al.,  1979);  whereas  the  concentrations  of  DAPBT, 
L682777,  L683685,  and L6383696 required to block TGF-13 
production were 10-20-fold higher than those for direct inhi- 
bition ofBAEC TGase (data not shown). Only retinol-treated 
BAECs, but not BSMCs or BESFs, both activate LTGF-13 
and express high levels of TGase and PA. The observation 
indicates that retinoids induce LTGF-~ activation in BAECs 
through enhancement of both PA and TGase levels.  Further 
support for the involvement of TGase in LTGF-13 activation 
derives from the observation that inhibitors of TGase and an 
antibody to TGase potentiate retinol-induced PA production 
presumably via the suppression of endogenous TGF-13 for- 
mation that normally results in an increase of PAI-1 levels. 
This effect was obvious after a 24-h treatment of cells with 
retinol. 
Although we have demonstrated that the increase of both 
PA and TGase levels in ECs by retinoids is associated with 
LTGF-13 activation in homotypic BAEC cultures, we cannot 
adopt this as an explanation for LTGF-13  activation by cocul- 
tures of ECs with SMCs as neither PA nor TGase levels in- 
crease dramatically during the time of coculture of BAECs 
and BSMCs (data not shown). However,  it is possible that 
these  enzymatic activities  are  increased  at  specific  sites 
where ECs and SMCs are in contact. Preliminary data indi- 
cate that coculture induces LTGF-13 activation more rapidly 
(2-6 h) than do retinoids 08-36 h). Thus, a rapid change oc- 
curs upon coculture of ECs and SMCs, resulting in TGase- 
and  plasmin-mediated  activation  of  LTGF-/3, whereas 
retinoid-induced  activation  follows  an  enhancement  of 
TGase and PA synthesis that takes place over a period of 
hours. It is also noteworthy that we were not able to induce 
LTGF-/3 activation by  adding guinea pig  liver  TGase  to 
homotypic cultures of BAECs (data not shown). This sug- 
gests two possibilities: one, there is a species specificity for 
TGase action and two, there are additional requirements for 
activation. These possibilities are presently being examined. 
The  regulation  of cell  growth  and  differentiation has 
emerged as a  putative function for type II TGase as two 
groups  have  reported  that TGase  activity increases  with 
decreasing cell growth (Birckbichler and Patterson,  1978; 
Milhaud et al.,  1980).  However,  little is known about the 
molecular mechanisms whereby type II TGase might control 
cell growth (Thacher and Rice,  1985;  Lichti et al.,  1985; 
Chiocca et al., 1989; Suedhoff et al.,  1990).  Although it is 
possible that type II TGase controls cell growth through its 
GTPase activity (Lee et al.,  1989),  the regulation of phos- 
pholipase A2 and its inhibitor (Cordella-Miele et al.,  1990; 
Ando et al., 1991), or the modulation of extracellular matrix 
function by cross-linking matrix proteins such as fibronec- 
tin, collagen, fibrinogen/fibrin, proteoglycan, and vitronec- 
tin (Martinez et al.,  1989; Kinsella and Wight, 1990;  Sane 
et al., 1991), our findings may directly explain the negative 
relationship between type II TGase and cell growth by link- 
ing TGase activity with the formation of TGF-/3, a potent 
growth inhibitor. This hypothesis predicts that older cells 
produce higher levels of TGF-/3 and that TGF-/3 is a growth 
inhibitor for these cells. This is currently being tested. 
It will be of interest to determine if cell-associated TGase 
is required for the formation of active TGF-/3 in other sys- 
tems such as osteoclasts and keratinocytes treated with reti- 
noids (Oreffo et al.,  1989; Glick et al.,  1989),  ECs treated 
with bleomycin (Phan et al., 1991), and human breast cancer 
cells treated with anti-estrogens (Colletta et al.,  1991). We 
have shown that TGase is required for LTGF-13  activation ob- 
served when BAECs are treated with basic fibroblast growth 
factor (data not shown). Thus, in three systems in which ECs 
have been shown to produce active TGF-/3, a requirement for 
TGase exists. 
According to our model for LTGF-/3 activation, the activa- 
tion takes place on the cell surface or matrix where the com- 
ponents required for activation form an assemblage of mole- 
cules that promotes the reaction (Dennis and Rifkin, 1991; 
Flaumenhafi et  al.,  1993).  Therefore,  TGase,  normally 
found intracellularly, must exist on the cell surface in order 
to participate in the activation process.  The ability of the 
aTGase IgG to inhibit LTGF-/3 activation is consistent with 
this proposal. Although we have no direct evidence to verify 
the extracellular deposition of TGase, Martinez et al. (1989) 
and Sane et al. (1991) recently demonstrated the cross-link- 
ing of fibrinogen and vitronectin, respectively, using human 
umbilical vein EC suspensions and suggested the existence 
of  cell-associated TGase in ECs. Also, the existence of  extra- 
cellular matrix-bound TGase was reported in wounded em- 
bryonic human lung fibroblasts (Upchurch et al., 1991). The 
mechanism by which TGase is involved in LTGF-/3 activation 
remains to be elucidated. Bendixen et al. (1991) recently re- 
ported that TGase cross-links plasminogen to fibronectin. It 
is possible that TGase concentrates plasminogen on the extra- 
cellular matrix.  Furthermore,  it is  also  possible  that the 
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LTGF-/~ binding protein by the type II TGase. Preliminary 
experiments indicate that semipurified LTGF-fl  without bind- 
ing protein as well as binding protein portion of  LTGF-B from 
human platelets is a substrate for guinea pig liver TGase (Ko- 
jima, S.,  unpublished  observation). 
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